HURA READ THE FULL HURA RESEARCH REPORT We are initiating coverage of TuHURA Biosciences, Inc. (NASDAQ:HURA) with a valuation of $9.25 per share. This value is based on our estimates for successful ...

Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer treatment, is approaching a critical juncture in its development ...

This class of biologic may work particularly well in blood cancers with mutated nucleophosmin 1 (NPM1). The antibody may be combined with a delta opioid receptor (DOR) inhibitor and/or a menin ...